Cover Image
市場調查報告書

中國的Leuprorelin市場

Investigation Report on China Leuprorelin Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 337517
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Leuprorelin市場 Investigation Report on China Leuprorelin Market, 2010-2019
出版日期: 2015年08月18日 內容資訊: 英文 30 Pages
簡介

Leuprorelin,進入中國市場之後,急速成長。年度銷售額從2005年的2,000萬人民幣,到2014年達2億6,000萬人民幣,以年複合成長率37%成長。

本報告提供中國的Leuprorelin市場相關調查分析、市場規模、市場佔有率、零售價格、主要製造商、市場預測等相關的系統性資訊。

第1章 Leuprorelin的相關概念

  • 適應
  • 全球市場銷售情形

第2章 中國的Leuprorelin的市場簡介

  • 中國的Leuprorelin的專利、核準情況
  • 主要製造商
  • 市場規模

第3章 中國的Leuprorelin銷售狀況分析

  • 銷售額
  • 銷售額數量

第4章 中國的Leuprorelin主要廠商的市場佔有率分析

  • 市場佔有率:各銷售額
  • 市場佔有率:各銷售數量

第5章 中國的Leuprorelin的各劑型分析

  • 市場佔有率 (各劑型) :各銷售額
  • 市場佔有率 (各劑型) :銷售額各數量

第6章 中國的Leuprorelin的醫院用標準價格

  • Shanghai Livzon Pharmaceutical Co., Ltd.
  • Beijing Biote Pharmaceutical Co., Ltd
  • 武田藥品工業 (日本)

第7章 中國的Leuprorelin市場主要製造商

  • Shanghai Livzon Pharmaceutical Co., Ltd.
  • Beijing Biote Pharmaceutical Co., Ltd
  • 武田藥品工業 (日本)

第8章 中國的Leuprorelin市場預測

  • 市場規模的預測
  • 競爭情形的預測

圖表

目錄
Product Code: 1508300

Originally developed by Takeda Pharmaceutical Co., Ltd, leuprorelin is a polypeptide used to treat prostate cancer and so on. Leuprorelin can inhibit pituitary gland and release gonadotropin Leuprolide acts as an agonist at pituitary GnRH receptors, leading to hypogonadism and thus a dramatic reduction in estradiol and testosterone levels in both sexes.

Having been marketed in 1994 for the first time, leuprorelin entered China under the trade name of enantone in 2000. As it is the specific drug for such sex hormone-related diseases as prostate cancer and endometriosis, it grows fast in China. Due to the technology involved in production of polypeptide, there was no generic drug for a long time despite its lack of patent protection in China. Currently, only generic drugs of Beijing Biote and Livzon are approved.

Leuprorelin develops fast after entering China with sales value in sample hospitals rising from about CNY 20 million in 2005 to over CNY 260 million in 2014 and CAGR during the period of 2006-2010 reaching 37%. Leuprorelin enjoys a vast demand in China. And Livzon, Beijing Biote Pharmaceutical Co., Ltd and Takeda Pharmaceutical Co., Ltd (Japan) occupy the market, among which Takeda Pharmaceutical Co., Ltd (Japan) had the largest market share of nearly 60% for sales value in 2014.

Due to unreliable heat of diet, Chinese children report increasingly obvious symptoms of sexual precocity, which is bad for their healthy development and attracts more and more parents' attention. In recent years, such problems as female fibroid caused by abnormal secretion of hypophyseal hormone have become increasingly prominent. As these problems are increasingly emphasized, leuprorelin which regulates the secretion of gonadotropins will enjoy a vast market. Since Lee's Pharmaceutical Holdings Limited is now the only company which applied to produce generic drugs of leuprorelin, there are still opportunities for future generic drugs.

Readers can get at least the following information through this report:

  • market size of leuprorelin in China
  • competitive landscape of leuprorelin market in China
  • price of leuprorelin made by different enterprises in China
  • market outlook of leuprorelin in China

The author suggests the following groups of people purchase this report:

  • manufacturers of polypeptide drugs
  • investors/research institutions interested in Chinese medicine market
  • -any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Leuprorelin

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Leuprorelin in China

  • 2.1. Patent Status and Approval Information of Leuprorelin in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Leuprorelin Sales in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Leuprorelin Manufacturers in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Leuprorelin in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Leuprorelin in Chinese Hospitals in 2014

  • 6.1. Shanghai Livzon Pharmaceutical Co., Ltd.
  • 6.2. Beijing Biote Pharmaceutical Co., Ltd
  • 6.3. Takeda Pharmaceutical Co., Ltd (Japan)

7. Major Manufacturers of Leuprorelin in Chinese Market

  • 7.1. Shanghai Livzon Pharmaceutical Co., Ltd.
  • 7.2. Beijing Biote Pharmaceutical Co., Ltd
  • 7.3. Takeda Pharmaceutical Co., Ltd (Japan)

8. Market Outlook of Leuprorelin in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Information of Leuprorelin in China
  • Chart Approval Information of Leuprorelin in China
  • Chart Leuprorelin Sales in China
  • Chart Sales Value of Leuprorelin in China
  • Chart Sales Value of Leuprorelin in Some Regions in China, 2010-2014
  • Chart Sales Volume of Leuprorelin in China, 2010-2014
  • Chart Sales Volume of Leuprorelin in Some Regions in China, 2010-2014
  • Chart Market Share of TOP3 Leuprorelin Manufacturers for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Leuprorelin Made by Livzon in China, 2010-2014
  • Chart Sales Value and Market Share of Leuprorelin Made by Beijing Biote in China, 2010-2014
  • Chart Sales Value and Market Share of Leuprorelin Made by Takeda (Japan) in China, 2010-2014
  • Chart Price of Leuprorelin Made by Livzon in Some Chinese Cities in 2014
  • Chart Price of Leuprorelin Made by Beijing Biote Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Leuprorelin Made by Takeda Pharmaceutical Co., Ltd (Japan) in Some Chinese Cities in 2014
Back to Top